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Research articleExperimental stress in inflammatory rheumatic 
diseases: a review of psychophysiological stress 
responses
Sabine JM de Brouwer*1, Floris W Kraaimaat1, Fred CGJ Sweep2, Marjonne CW Creemers3, Timothy RDJ Radstake3, 
Antoinette IM van Laarhoven1, Piet LCM van Riel3 and Andrea WM Evers1
Abstract
Introduction: Stressful events are thought to contribute to the aetiology, maintenance and exacerbation of rheumatic 
diseases. Given the growing interest in acute stress responses and disease, this review investigates the impact of real-
life experimental psychosocial, cognitive, exercise and sensory stressors on autonomic, neuroendocrine and immune 
function in patients with inflammatory rheumatic diseases.
Methods: Databases Medline, PsychINFO, Embase, Cinahl and Pubmed were screened for studies (1985 to 2009) 
investigating physiological stress responses in inflammatory rheumatic diseases. Eighteen articles met the inclusion 
criteria.
Results: Results suggest that immune function may be altered in response to a stressor; such alterations could 
contribute to the maintenance or exacerbation of inflammatory rheumatic diseases during stressful events in daily life.
Conclusions: This review emphasizes the need for more experimental research in rheumatic populations with 
controlled stress paradigms that include a follow-up with multiple evaluation points, simultaneous assessment of 
different physiological stress systems, and studying factors contributing to specific physiological responses, such as 
stress appraisal.
Introduction
Stress is widely recognized as an important risk factor in
the aetiology of inflammatory rheumatic diseases [1-5].
An adaptational stress response involves the activation of
both the hypothalamus-pituitary-adrenal axis (HPA axis)
[6] and the autonomic nervous system (ANS) [7], and
both stress axes are thought to communicate bidirection-
ally with the immune system [7-10]. Because many rheu-
matic diseases are characterized by immune-mediated
joint inflammation, stressful events might contribute to
the aetiology, maintenance and exacerbation of rheu-
matic diseases [11,12]. Recent advances in psychoneu-
roimmunology have provided insight into the complex
mechanisms by which stressors might acutely affect the
body's immune system [13-16]. However, little attention
has been paid to whether and how different short-term
experimental stressors influence the separate pathways of
the physiological stress response system (ANS, HPA axis,
immune system) in patients with inflammatory rheu-
matic diseases.
Perception of an external stressful stimulus prompts
the activation of various physiological systems that
together define the body's stress response, which is aimed
at re-establishing homeostasis. The physiological stress
response is mainly coordinated by the hypothalamus,
with activation of the ANS and the pituitary and adrenal
glands (HPA axis) resulting in the release of cate-
cholamines and cortisol, respectively [1,9,17]. These
stress hormones, supposedly acting via β- and α-adrener-
gic as well as glucocorticoid receptors, down-regulate
immune and inflammatory processes; however, these
processes also influence the central nervous system
(CNS) [7,18-20]. Circulating cytokines (for example,
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tumor necrosis factor α (TNF-α), interleukin (IL)-6 and
IL-1) and activated immune cells, markers of inflamma-
tion, activate both (intermediates of ) the HPA axis and
the ANS. Chronically elevated levels of cytokines, as
occur during long-term inflammation, might lead to
changes in HPA axis and ANS activity [21]. Moreover, the
bidirectional relationship between the CNS and immune
system implies that the physiological response to real-life
stressors could contribute to the pathophysiology of
inflammatory diseases [1-5]. How these three systems,
the ANS, the HPA axis and the immune system, act in
response to a stressful event in rheumatic disorders is not
well understood.
Although the laboratory setting is not a natural envi-
ronment, it allows control of key factors in the delivery of
stress and observation of its effects and reduces many
sources of bias and individual differences [16,22]. The lit-
erature on acute psychoneuroimmunological and psy-
choendocrinological responses to experimental stress in
healthy individuals is still increasing. Studies of healthy
populations suggest that experimental psychological and
physical stressors not only activate the ANS [23] and the
HPA axis [24], but also influence the immune system by
activating innate immunity, as reflected by increased
numbers of natural killer (NK) cells and the production of
pro-inflammatory IL-6 [15,16]. Moreover, these different
physiological systems (ANS, HPA axis and immune sys-
tem) seem to work in an interdependent fashion [25].
Despite the possible detrimental physiological effects of
stress in patients with inflammatory rheumatic diseases,
such as an altered disease course, little is known about
acute-phase reactants of experimentally induced stress
(both autonomic, neuroendocrine and immune). Reviews
of acute physiological stress responses have either
focussed on one [16,24] or two [2] stress response sys-
tems only (for example, ANS and/or neuroendocrine sys-
tem), and included either only patients with rheumatoid
arthritis [2] or a heterogeneous group of both healthy
participants and various patient populations [16]. In
addition, studies of the relationship between stress and
inflammatory rheumatic diseases have often used experi-
mental stressors that do not necessarily mimic real-life
stressors. Different types of time-limited experimental
stressors have been identified, namely, physical stressors
(autonomic function tests, exercise), physiological stres-
sors (corticotropin-releasing hormone (CRH) and
(nor)epinephrine infusions, insulin tolerance test and
dexamethasone suppression test) and psychological
stressors (cognitive tests, public speaking) [2]. Many
studies have investigated the effects of these types of
stress on components of the stress response system, such
as the ANS or the HPA axis, but external validity of these
studies of stress is questionable. The prevalence of car-
diovascular dysfunction is high after standard tests of
autonomic function [26], such as the Valsalva manoeuvre,
deep breathing, orthostatic tests, and sustained handgrip.
While these tests may trigger autonomic responses, it is
not known whether they activate the stress response sys-
tem and alter neuroendocrine or immune function. HPA
axis function has been investigated extensively by chal-
lenging specific parts of the HPA axis by means of infu-
sion of CRH, synthetic glucocorticoids, or cytokines
[27,28]. Although alterations in HPA axis responsiveness
at a hypothalamic, pituitary or adrenal level have been
reported, more subtle changes in HPA functioning have
also been suggested to occur [27,28]. While injection
studies might shed some light on possible altered neu-
roendocrine responses, the anti-inflammatory effects of
exogenously administered glucocorticoids are not neces-
sarily mirrored by increased secretion of endogenous glu-
cocorticoids in response to a real-life stressor. Thus the
question remains to what extent different types of experi-
mental stressors that mimic real-life stressful events (for
example, psychological stressors and physical exercise)
are able to induce an autonomic, neuroendocrine and
immune response in patients with inflammatory rheu-
matic diseases.
To the best of our knowledge this is the first review to
investigate whether and how different experimental stres-
sors mimicking real-life stressful events (psychosocial,
cognitive, exercise and sensory stressors) influence physi-
ological responses at the three levels (ANS, HPA-axis,
immune system) in patients with prototypic inflamma-
tory rheumatic diseases (for example, rheumatoid arthri-
tis (RA) and systemic lupus erythematosus (SLE).
Materials and methods
This review is limited to studies involving patients with
inflammatory rheumatic diseases who were exposed to a
time-limited experimental stressor to assess the auto-
nomic, neuroendocrine, and/or immune responses to
stress.
Search strategy
To identify studies, the electronic bibliographic databases
MEDLINE, PsychINFO, Embase, Cinahl and Pubmed
databases were searched, using the key words rheum*,
(idiopathic or psoriatic) arthr*, spondylitis, sclerosis and
lupus in combination with the terms stress and either cor-
tisol or immun* or epinephrine or endocrin* or autonom*
or hypothalam* or HPA. In addition, reference sections of
the articles and review papers were hand-searched for
relevant articles on psychological and physical stressors
and inflammatory rheumatic diseases.
Inclusion criteria were studies published after 1985 in
English peer-reviewed journals; evaluation of an experi-
mental laboratory stress task that induces psychological
and/or physical (exercise) stress and/or sensory stress (for
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example, thermoceptive (cold/heat), visual (light), audi-
tive (noise)) by means of a time-limited experimental
stressor; patients diagnosed with systemic inflammatory
rheumatic diseases, such as RA, juvenile idiopathic
arthritis (JIA), ankylosing spondylitis, systemic sclerosis,
or SLE; control group consisting of either healthy partici-
pants or participants without a systemic inflammatory
rheumatic disease, such as osteoarthritis; use of
(neuro)endocrine variables (for example, cortisol levels),
ANS variables (for example, heart rate, skin conductance,
(nor)epinephrine levels), or immune variables (for exam-
ple, number of leucocytes or lymphocytes, subsets of
lymphocytes, interleukin levels) as outcomes. Exclusion
criteria were pharmacological studies involving CRH,
glucocorticoids, insulin or (nor)epinephrine infusions;
studies evaluating a battery of standard autonomic func-
tion tests, which include deep breathing, the Valsalva
manoeuvre, posture changes, and sustained handgrip,
unless they were part of a paradigm with a psychological
and/or exercise and/or sensory stressor [29-33]; assess-
ment of anaerobic threshold, peak oxygen consumption,
lactate threshold [34,35], fibrinogen and prothrombin
time [36]. If a research group published more than one
article on the same experimental study but evaluated dif-
ferent outcome measures, both articles were included in
the review [29,30,36,37].
Conclusions were based on (uni- or multivariate) statis-
tics for within-group and/or between-groups differences.
If studies reported significant between-group differences
in repeated measures ANOVAs, baseline values between
groups were assumed to be different, unless stated other-
wise. If studies did not report significant (within- or
between-) group differences, it was assumed that none
were found. If studies did not provide statistical analyses,
findings were based on mean (± standard error of the
mean (SEM) or standard deviation (SD)) or median val-
ues. If those values were ambiguous, no conclusions were
drawn.
Results
Participants
Patient groups
Sixteen studies (18 articles) met the inclusion criteria.
The study sample characteristics are summarized in
Table 1. Nine studies included patients with RA
[29,30,34-42] and seven patients with SLE
[31,33,35,40,43-45]. Two of these studies involved both
types of patients [35,40]. In addition, one study included
patients with JIA [46] and one study included a heteroge-
neous group of patients with inflammatory arthritis (RA,
psoriatic arthritis, ankylosing spondylitis and fibrositis)
[32]. Fifteen studies included healthy participants with-
out systemic inflammatory rheumatic disease as control
and one study, patients with osteoarthritis [36,37]. In
three studies a second control group was added, consist-
ing of either patients with myofascial pain [32], patients
with sarcoidosis [43], or participants taking corticoster-
oids [44]. Most studies have relatively small sample sizes
(N = 10 to 20 per group), with even smaller sample sizes
(N <10) in two studies [35,40]. In addition, patient sam-
ples are probably heterogeneous because, for example,
strict exclusion criteria regarding comorbidities are lack-
ing in half of all studies [32,33,35,38,42-44,46]. With
regard to diagnostic criteria, one study even included also
patients with non-inflammatory arthritis [32]. There is
also a high variability in pharmacotherapy profiles, but
overall these profiles were well-defined for the various
classes of drugs (see Table 1), except in two studies
[32,33]. To control for the effects of pharmacotherapy
some studies excluded patients using specific medication
(for example, corticosteroids [35,38-40,46], opioids
[39,41], antidepressants [39,40,45], or adrenoceptor
antagonists [29,40,45]), or the intake of medication was
regulated prior to and on the day of testing [39,41]. In
addition, two studies performed subgroup analyses with
patients on different medical regimes [41,45].
Stress paradigms
The stressors included in this review were experimental
manipulations of stressful experiences, either of a psy-
chological, exercise and/or sensory nature, and lasted
between one minute and two hours.
Psychological stressors
Ten of 16 studies used a psychological stressor, applied
for one minute to two hours [29-32,36-38,40,41,43-45].
Cognitive stressors Seven studies used cognitive stres-
sors [29-32,36-38,42,44], namely, the Stroop Color-Word
Interference test [29,30,38]; a two-minute cognitive dis-
crimination task [29,30]; the Attention and Concentra-
tion Test, Syndrome Short Test, computerized-controlled
Reaction Time Task and three parts of the Hamburg
Wechsler Adult Intelligence Test (comprehension, digit
span, block design) [42,44]; Multiple Choice Word Flu-
ency; and the Benton Visual Memory Scale [44]. Mental
arithmetic was assessed in two studies, either with a one-
or two-minute serial subtraction task [31,32], or with a
two-minute paced auditory serial addition test performed
while patients were tilted to a head-up-tilt of 64 degrees
[36,37].
Psychosocial stressors Three studies used a psychoso-
cial stressor, namely, a 10-minute public speaking task
[40]; the Trier Social Stress Test consisting of a five-min-
ute public speech and a five-minute public mental sub-
traction task [41]; or a ten-minute public speech
(including a five-minute preparation period) on the topic
'Children in today's society' [45].
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Table 1: Study sample characteristics
Study Patient sample Control sample Pharmacotherapy of patient sample
NSAIDs DMARDs Cortisteroids Biologicals Other Pharmacotherapy 
comments:
Dekkers et al., 2001 [38] N = 29 RA patients;
No exclusion criteria given
N = 30 HC;
Age and sex matched;
Exclusion: chronic 
disease, chronic pain, 
heart problems, 
hypertension
+ + -1 o o 1 patients taking oral 
prednisone (5-15 mg) or 
corticosteroid injections < 3 
months prior to study onset 
excluded
Edwards et al., 2009 [39] N = 19 RA patients;
Exclusion: history of myocardial infarction 
or cardiovascular disease, peripheral 
neuropathy, Raynaud syndrome, vasculitis, 
peripheral vascular disease, other 
autoimmune or rheumatic disorders, 
current infection, recent history of 
substance abuse or dependence, 
pregnancy, mood or anxiety disorder
N = 21 HC;
No age and sex 
difference with patients;
Same exclusion criteria 
as patients;
+2 + - + -3 2 24 h prior to study onset 
no NSAIDs intake;
3 Opioids, antidepressants 
excluded;
Stable medication regime 
of >1 months
Geenen et al., 1996/
1998 [29,30]
N = 21 RA patients;
Exclusion: other serious diseases
N = 20 HC;
Age and sex matched; 
Exclusion: chronic pain, 
cardiovascular 
complaints, chronic 
diseases
+ + o o -4 4 α and β adrenoceptor 
antagonists excluded (only 
for autonomic response 
evaluation)
Hinrichsen et al., 1989 
[43]
N = 14 SLE patients;
No exclusion criteria given
N = 14 HC, N = 12 
sarcoidosis patients;
Age and sex matched;
o o +5 o o 5 24 h prior to study onset 
no corticosteroid therapy;
Hinrichsen et al., 1992 
[44]
N = 14 SLE patients;
No exclusion criteria given
N = 14 HC, N = 10 HC 
taking corticosteroids;
Age and sex matched
o o +6 o o 6 4-10 mg; 24 h prior to 
study onset no 
corticosteroid therapy
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Hogarth et al., 2002 [31] N = 23 SLE patients;
Exclusion: diabetes mellitus, hypertension 
Remark: some patients have comorbid 
Sjogren syndrome, Raynaud's 
phenomenon, history of cerebral lupus
N = 23 HC;
Age and sex matched;
Exclusion: diabetes 
mellitus, hypertension
+ + +7 o -8 7 1-30 mg;
8 Antihypertensive 
medication <1 week prior 
to study excluded
Jscobs et al., 2001 [40] N = 9 RA patients, N = 7 SLE patients;
Exclusion: significant cardiovascular 
diseases, concurrent infections, history of 
other autoimmune disorders, drug or 
alcohol abuse; no exacerbation of disease < 
4 weeks
N = 15 HC;
Age and sex matched;
Same exclusion criteria 
as patients
o + - - -9 9 adrenoceptor antagonists, 
antidepressants and 
benzodiazepines taken < 4 
weeks prior to study onset 
excluded
Kurtais et al., 2006 [34] N = 19 RA patients;
Exclusion: severe illness, other general 
contraindications for graded exercise test
N = 14 HC;
Age and sex matched;
Inclusion: sedentary 
Exclusion: chronic 
systemic disease, 
chronic pain, 
contraindication for 
exercise test
+ + +10 o o 10 7.5-15 mg;
Motivala et al., 2008 [41] N = 21 RA patients;
Exclusion: cardiovascular disease, 
endocrine-related other immune disorders, 
acute or chronic infections, pregnancy, 
current psychiatric mood or anxiety 
disorder
N = 20 HC;
Age and sex matched;
Same exclusion criteria 
as patients
+11 + +12 + -13 11 24 h prior to study onset 
no NSAIDs taken;
12 < 10 mg (> 10 mg 
excluded);
13 Opioids, oral 
contraception excluded;
Stable medication regime 
>2 months
Palm et al., 1992 [42] N = 18 RA patients;
No exclusion criteria given
N = 14 HC;
Age and sex matched;
Half of all controls had 
been hospitalized 
because of coronary 
heart disease or 
hypertension
+ + +14 o o 14 2,5-10 mg
Table 1: Study sample characteristics (Continued)
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Pawlak et al., 1999 [45] N = 15 SLE patients (N < 10 for subanalyses: 
NK cytotoxicity and # β-adrenoceptors);
Exclusion: significant cardiovascular 
diseases, concurrent infections, history of 
other autoimmune disorders, drug or 
alcohol abuse
N = 15 HC (N < 10 for 
subanalyses: NK 
cytotoxicity and # β-
adrenoceptors);
Age and sex matched;
Same exclusion criteria 
as patients
o + +15 o -16 15 5-10 mg;
16 Adrenoceptor 
antagonists, 
antidepressants, 
benzodiazepines taken < 4 
week prior to study onset 
excluded
Perry et al., 1989 [32] N = 19 heterogeneous group of arthritis 
patients (RA, psoriatic arthritis, ankylosing 
spondylitis, fibrositis);
No exclusion criteria given
N = 38 HC, 17 patients 
with myofascial pain;
No exclusion criteria 
given
+ o O o +17 17 Benzodiazepines, 
psychotropics, and other 
medication affecting ANS, 
etc; 12 h prior to onset 
study no medication taken 
known to affect ANS
Pool et al., 2004 [35] N = 7 RA patients, N = 6 SLE patients;
No exclusion criteria given
N = 10 HC;
HC recruited from 
hospital staff;
No exclusion criteria 
given
+ + - o -18 18 Phenothiazines (e.o. 
drugs influencing PRL 
levels) excluded
Roupe et al., 2000 [46] N = 20 JIA patients (N = 15 for in vivo 
analyses);
No exclusion criteria given
N = 20 HC (N = 14 for in 
vivo analyses);
Age and sex matched;
+ + - o o
Shalimar et al., 2006 [33] N = 51 SLE patients;
No exclusion criteria given
N = 30 HC;
Age and sex matched
o o O o -19 19 Medication known to 
affect HR, BP excluded
Veldhuijzen et al., 2005/
2008 [36,37]
N = 21 RA patients;
Exclusion: previously confirmed acute 
coronary syndrome, DM, serious psychiatric 
diseases
N = 10 OA patients;
Same exclusion criteria 
as patients
+ + + + +20 20 Analgesics included; no 
use of oral contraception
RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, HC = healthy controls, JIA = juvenile idiopathic arthritis, OA = osteoarthritis, DM = diabetes mellitus. + = Included; - = Excluded; o = 
Not mentioned in article. ANS = autonomic nervous system, BP = blood pressure, DMARDs = disease-modifying antirheumatic drugs, HR = heart rate, NSAIDs = nonsteroidal anti-inflammatory 
drugs, PRL = prolactin.
Table 1: Study sample characteristics (Continued)
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Exercise stressors
Three studies used exercise stressors, namely, a bicycle
ergometer task, which involved cycling at a rate of 50 rev-
olutions per minute against a resistance of 12.5 watt for
three minutes [38]; or an ergospirometric exercise test on
a treadmill to the limit of subject's tolerance for several
minutes [34,35].
Sensory stressors
Eight studies assessed sensory stressors, most of which
used thermal stimuli, usually experienced as painful. Five
studies assessed responses to a cold stressor
[31,33,38,39,46], in which participants either had to put
their hand in a bowl filled with (ice) cold water for several
minutes [38,39,46], or endure an ice-pack on their hand
[31]. One study did not describe the cold pressor task
[33]. Heat pulses [39], an acoustic stress test (several min-
utes) [42,43] and a pupillary light flash test [32] were also
used.
Outcome measures
Outcome measures were self-reported distress, autono-
mous nervous system responses, neuroendocrine
responses, or immune responses (see Tables 2, 3 and 4).
Self-reported distress
Stress-induced self-reported distress was assessed in only
two of 16 studies [41,45]. Subjective distress levels were
either measured on a visual analogue scale (VAS) ranging
from 0 to 100 [41] or on a VAS tension and excitement
together with the State Trait Anxiety Inventory (STAI)
[45].
Measures of the autonomous nervous system
Eleven studies assessed ANS responses (see Table 2)
[29,31-33,37,40-43,45,46], namely, heart rate
[29,31,32,37,41,45], diastolic and/or systolic blood pres-
sure [29,31,33,41,45], mean arterial pressure, systemic
vascular resistance, plasma volume and cardiac output
[36,37], and pre-ejection period (PEP) [41]. Furthermore,
plasma (nor)epinephrine levels [31,40,42,44-46] and skin
conductance [29,32] were assessed.
Endocrine measures
Eight studies assessed neuroendocrine responses (see
Table 3) [30,34,35,38,39,41,42,44], namely plasma
[30,34,38,41,42,44] or serum [35,39] cortisol levels and
plasma ACTH levels [34,38,41]. Two studies measured
hormones other than those involved in the HPA axis,
namely, plasma growth hormone (GH) and insulin-like
growth factor I (IGF-I) levels [34] and serum prolactin
levels [35].
Immunological measures
Twelve studies assessed immune responses (see Table 4)
[30,35,36,38-46], namely, the total number of leucocytes
[36,40,42-45], and the number of lymphocytes and/or
subsets of lymphocytes, including B cells, T cells and NK
cells [30,35,40,42-45]. Two studies assessed NK cell cyto-
toxicity [40,45]. Six studies reported on cytokine levels
[38-42,46], namely, plasma levels of cytokine IL-1β [42],
IL-6 [39,41,42] and TNF-α [39], ex vivo stimulated mono-
nuclear cell production of IL-2 [40], IL-4 [38,40], IL-6
[40,41,46], IL-8 [46], IL-10 [40], interferon (IFN)-γ
[38,40] and TNF-α [41], or intracellular concentrations of
IL-4, IL-6, IL-10 and IFN-γ [40]. Other inflammation
markers were also assessed, such as C-reactive protein
(CRP) [36], the number of β-adrenoceptors on mono-
cytes [45], β-adrenoceptor sensitivity [45], and plasma
soluble IL-2 receptor levels [42].
Time points of outcome measures
All studies reported baseline values for the outcome mea-
sures, and all, except two [32,34], reported a resting
period of 3 to 45 minutes. During administration of the
experimental stressor, physiological reactivity was either
assessed at specific time points (in three studies)
[35,41,42], or continuously throughout the stress proce-
dure (only for autonomic measures such as heart rate,
blood pressure and/or skin conductance; in four studies)
[29,32,37,45]. All studies reported immediate post stress
measurements, except two studies that only assessed
stress reactivity at 30 minutes [34] or 60 minutes [35]
after cessation of the stressor. Eight of 16 studies have one
[29,30,36-38,40,45] or more [39,41,46] additional follow-
up measurement points, ranging from 5 to 60 minutes
after cessation of the stressor.
Baseline characteristics
Autonomic, neuroendocrine, and immune functions
were assessed at baseline in patients with rheumatic dis-
orders and controls. Results for the separate outcome
measures are summarized in Tables 2, 3 and 4.
ANS variables
ANS function at baseline was not different between
patients with rheumatic disorders and controls in most
studies. Cardiovascular variables, skin conductance, and
catecholamine levels did not differ in nine studies
[29,31,36,37,40-42,44-46], whereas three studies reported
significantly higher levels of autonomic activity at base-
line (heart rate and pupil area [32]; epinephrine levels
[46]) or lower levels ((nor)epinephrine [31]) in patients
with rheumatic disorders compared with controls (see
Table 2).
Neuroendocrine variables
Neuroendocrine function at baseline was not signifi-
cantly different between patients with rheumatic disor-
ders and controls. Five of eight studies reported similar
baseline levels of cortisol, ACTH, GH, IGF-I, and prolac-
tin [34,35,39,41,42]. Three studies reported higher levels
of cortisol at baseline (in patients with RA) [30,38] or
lower levels (in patients with SLE) [44] than in controls
(see Table 3). Lower cortisol levels at baseline were also
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Table 2: Autonomic function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patients vs. controls Stress reactivity within patients Stress reactivity patients vs. controls
Heart rate [29] 21 RA vs. 20 HC RA: No difference 
[29,36,37,41]
RA: Increase [29,36,37,41] RA: No difference [36,37,41]
[41] 21 RA vs. 20 HC Altered (↓) [29]
[36,37] 21 RA vs. 10 OA SLE: No difference [31,45] SLE: Increase [45] SLE: No difference [31] (cogn.) [45]
[31] 23 SLE vs. 23 HC Not reported [31] Altered (↓) (cold) [31]
[45] 15 SLE vs. 15 HC Arthr: Altered (↑) [32] Arthr: Increase [32] Arthr: No difference [32]
[32] 19Arthr vs. 38 HC, 17 MFP
Blood pressure (diastolic/
systolic)
[29] 21 RA vs. 20 HC RA: No difference [29,36,41] RA: Increase [29,36,41] RA: No difference [36,41]
[41] 21 RA vs. 20 HC Altered (↓) [29]/(↑) [41]
[36] 21 RA vs. 10 OA SLE: No difference [31,45] SLE: Increase [45] SLE: No difference [31,33,45]
[31] 23 SLE vs. 23 HC Not reported [33] Not reported [31,33]
[45] 15 SLE vs. 15 HC
[33] 51 SLE vs. 30 HC
Mean arterial pressure (MAP) [37] 21 RA vs. 10 OA RA: No difference RA: Increase RA: No difference
Systemic vascular resistance 
(SVR)
[37] 21 RA vs. 10 OA RA: No difference RA: Increase severe subgroup RA: Altered (↑) severe subgroup
Plasma volume (PV) [36] 21 RA vs. 10 OA RA: No difference RA: Decrease RA: No difference
Cardiac output (CO) [37] 21 RA vs. 10 OA RA: No difference RA: No response RA: No difference
Pre-ejection period (PEP) [41] 21 RA vs. 20 HC RA: No difference RA: Decrease RA: No difference
Plasma catecholamines 
(nor)epinephrine
[42] 18 RA vs. 14 HC RA: No difference [40,42] * RA: Increase [40] RA: No difference [40,42]
[40] 9 RA, 7 SLE vs. 15 HC No response [42]
[44] 14 SLE vs. 14 HC, 10 HC SLE: No difference [40,45] SLE: Increase [40,44,45] SLE: No difference [40,45,44] *
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[31] 23 SLE vs. 23 HC Altered (↓) [31]
[45] 15 SLE vs. 15 HC Not reported [44]
[46] 15 JIA vs. 14 HC JIA: No difference (NE) [46] JIA: Increase (NE)[46] JIA: No difference [46]
Altered (↑) (EPI) [46] No response (EPI)[46]
Skin conductance (SC) [29] 21 RA vs. 20 HC RA: No difference [29] RA: Increase [29] RA: Altered (↓) [29]
[32] 19 Arthr vs. 38 HC, 17 MFP Arthr: No difference [32] Arthr: Increase [32] Arthr: Altered (↑) [32]
Pupillary constriction [32] 19 Arthr vs. 38 HC, 17 MFP Arthr: Altered (↓) Arthr: Not reported Arthr: Altered (↓)
* Findings assumed after inspection of descriptive data.
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern is diminished compared to a control group; RA = rheumatoid arthritis, SLE = systemic 
lupus erythematosus, JIA = juvenile idiopathic arthritis, Arthr = heterogeneous group of arthritis patients, HC = healthy controls, OA = osteoarthritis, MFP = patients with myofascial pain,.., NE = 
norepinephrine, EPI = epinephrine.
Table 2: Autonomic function in patients with systemic inflammatory rheumatic diseases (Continued)
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Table 3: Neuroendocrine function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
ACTH [38] 29 RA vs. 30 HC RA: No difference [34,38,41] RA: Increase [34,41] RA: No difference [34,38,41]
[34] 19 RA vs. 14 HC Not reported [38]
[41] 21 RA vs. 20 HC
Cortisol [30] 21 RA vs. 20 HC RA: No difference [34,35,39,41,42] RA: Decrease [34,35,42] RA: No difference [30,34,39,41,42]
[38] 29 RA vs. 30 HC Altered (↑) [30,38] Change [30] Altered (↓) [35,38]
[39] 19 RA vs. 21 HC No difference [35] Increase [39,41] No difference [44]
[34] 19 RA vs. 14 HC SLE: Altered (↓) [44] SLE: Decrease [35] SLE: Altered (↓) [35]
[41] 21 RA vs. 20 HC No response [44]
[42] 18 RA vs. 14 HC
[35] 7 RA, 6 SLE vs. 10 HC
[44] 14 SLE vs. 14 HC, 10 HC
Growth hormone (GH) [34] 19 RA vs. 14 HC RA: No difference RA: Increase RA: No difference
Insulin-like growth factor (IGF-I) [34] 19 RA vs. 14 HC RA: No difference RA: No response RA: No difference
Prolactin [35] 7 RA, 6 SLE vs. 10 HC RA: No difference RA: No response RA: Altered (↓)
SLE: No difference SLE: No response SLE: Altered (↓)
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern is diminished compared to a control group;
RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, HC = healthy controls, ACTH = adrenocorticotropin hormone,
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Table 4: Immune function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
Leucocytes [42] 18 RA vs. 14 HC
[36] 21 RA vs. 10 OA RA: No difference [36,40,42] RA: Increase [36,40,42] RA: No difference [36,40,42] *
[40] 9 RA, 7 SLE vs. 15 HC SLE: No difference [43,45,44] * SLE: Increase [40,43-45] SLE: Altered (↓) [40,43,45]
[43] 14 SLE vs. 14 HC, 12 SD Altered (↓) [40] No difference [44] *
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
Total lymphocytes [30] 21 RA vs. 20 HC RA: Altered (↓) [30,42] RA: Increase [30,40] RA: No difference [30,40]
[42] 18 RA vs. 14 HC No difference [40] No response [42] Altered (↓) [42]
[40] 9 RA, 7 SLE vs. 15 HC SLE: Altered (↓) [40,43,45] SLE: Increase [40,45] SLE: Altered (↓) [43-45]
[43] 14 SLE vs. 14 HC, 12 SD Not reported [44] No response[43,44] No difference [40]
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
Total T cells (CD3+) [30] 21 RA vs. 20 HC RA: No difference [40] RA: Increase [40] RA: No difference [30,40]
[40] 9 RA, 7 SLE vs. 15 HC Altered (↓) [30] No response [30]
[43] 14 SLE vs. 14 HC, 12 SD SLE: Altered (↓) [40,45] SLE: Increase [40,45] SLE: No difference [40,43]
[44] 14 SLE vs. 14 HC, 10 HC No difference (%) [43,44] * No response (%) [43,44] Altered (↓) [45]/(%) [44]
[45]15 SLE vs. 15 HC
Helper T cells (CD4+) [40] 9 RA, 7 SLE vs. 15 HC RA: No difference [35,40] RA: Increase [40] RA: Altered (↓) [35,40]
[35] 7 RA, 6 SLE vs. 10 HC Decrease [35]
[43] 14 SLE vs. 14 HC, 12 SD SLE: Altered (↓) [40,45] SLE: No response [40,45]/(%) [44] SLE: Altered (↓) [45] (%) [43,44]/(↑)
[44] 14 SLE vs. 14 HC, 10 HC No difference [35]/(%) [43] Decrease [35]/(%) [43] [35]
[45] 15 SLE vs. 15 HC Not reported [44] No difference [40]
Cytotoxic T cells (CD8+) [40] 9 RA, 7SLE vs. 15 HC RA: No difference [35,40] RA: Increase [40] RA: No difference [40]
[35] 7 RA, 6 SLE vs. 10 HC No response [35] Altered (↓) [35]
[43] 14 SLE vs. 14 HC, 12 SD SLE: Altered (↓)[40,45] SLE: Increase [40,45]/(%) [43,44] SLE: No difference [40,45,44] *
[44] 14 SLE vs. 14 HC, 10 HC No difference [35]/(%) [43] Decrease [35] Altered (↓) [35]/(%) [43]
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[45] 15 SLE vs. 15 HC Not reported [44]
B cells (CD19+) [30] 21 RA vs. 20 HC RA: Altered (↓) [30] RA: Increase [30] RA: No difference [30]
[43] 14 SLE vs. 14 HC, 12 SD SLE: Altered (↑) (%) [43] SLE: Increase (%) [43] SLE: Altered (↓) (%) [43,44]
[44] 14 SLE vs. 14HC, 10HC No difference (%) [44] * No response (%) [44]
NK cells (CD56+) [30] 21 RA vs. 20 HC RA: No difference [40] RA: Increase [30,40] RA: No difference [30,40]
[40] 9 RA, 7 SLE vs. 15 HC Altered (↓) [30]
[44] 14 SLE vs. 14 HC, 10 HC SLE: Altered (↓) [40,45] SLE: Increase [40,45] SLE: Altered (↓) [40,45]
[45] 15 SLE vs. 15 HC Not reported [44] No response [44] No difference [44]
NK cell cytotoxicity [40] 9 RA, 7 SLE vs. 15 HC RA: No difference [40] RA: No response [40] RA: Altered (↓) [40]
[45] 4 SLE vs. 8 HC SLE: No difference [40,45] SLE: No response [40,45] SLE: Altered (↓) [40,45]
Cytokines
IL-6 [39] 19 RA vs. 21 HC RA: No difference [40,41] RA: No response [40] RA: No difference [39-41]
[41] 21 RA vs. 20 HC Altered (↑) [39] Increase [39]
[42] 18 RA vs. 14 HC Decrease (not plasma) [41]
[40] 9 RA, 7 SLE vs. 15 HC SLE: No difference [40] SLE: No response [40] SLE: No difference [40]
[46] 15 JIA vs. 14 HC JIA: Altered (↑) [46] JIA: Increase [46] JIA: Altered (↑) [46]
IL-2 [40] 9 RA, 7 SLE vs. 15 HC RA: No difference RA: No response RA: No difference
SLE: No difference SLE: No response SLE: No difference
IL-4 [38] 29 RA vs. 30 HC RA: No difference [38,40] RA: No response [40] RA: No difference [40]
[40] 9 RA, 7 SLE vs. 15 HC SLE: No difference [40] SLE: Increase [40] SLE: Altered (↑) [40]
IL-8 [46] 15 JIA vs. 14 HC JIA: Altered (↑) JIA: No response JIA: No difference
IL-10 [40] 9 RA, 7 SLE vs. 15 HC RA: Altered (↓) (not intracell.) RA No response RA: No difference
SLE: Altered (↓) (not intracell.) SLE: No response SLE: No difference
IFN-γ [38] 29 RA vs. 30 HC RA: No difference [38] RA: No response [40] RA: Altered (↓) [40]
[40] 9 RA, 7 SLE vs. 15 HC Altered (↓) (not intracell.) [40]
SLE: Altered (↓)(not intracell.) [40] SLE: No response [40] SLE: Altered (↓) [40]
TNF-α [39] 19 RA vs. 21 HC RA: No difference [39,41] RA: Increase [39,41] RA: Altered (↑) [39,41]
Table 4: Immune function in patients with systemic inflammatory rheumatic diseases (Continued)
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[41] 21 RA vs. 20 HC
β-adenoceptors [45] 7 SLE vs. 8 HC SLE: No difference SLE: No response SLE: Altered (↓)
β-adrenoceptor sensitivity [45] 7 SLE vs. 8 HC SLE: Altered (↓) Not assessed Not assessed
sIL-2 receptor [42] 18 RA vs. 14 HC RA: Altered (↑) RA: No response RA: No difference
C-reactive protein (CRP) [36] 21 RA vs. 10 OA RA: No difference RA: Increase RA: Altered (↑)
* Findings assumed after inspection of descriptive data.
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern is diminished compared to a control group;
RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, JIA = juvenile idiopathic arthritis, HC = healthy controls, OA = osteoarthritis, SD = sarcoidosis patients. IL = interleukin, IFN-γ = 
interferon-γ, TNF-α = tumor necrosis factor α, sIL-2 receptor = soluble interleukin-2 receptor, intracell. = intracellular interleukin concentration on the single-cell level.
Table 4: Immune function in patients with systemic inflammatory rheumatic diseases (Continued)
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observed in one study in which control subjects were tak-
ing corticosteroids [44].
Immune variables
Baseline leucocyte counts [36,40,42] were not different
between patients with RA and controls. However, two of
three studies found patients with RA to have lymphope-
nia at baseline [30,42]. Levels of cytokines and other
inflammatory factors (IL-2, IL-4, IL-6, IFN-γ, TNF-α, and
CRP) were similar in patients with RA and controls in five
studies [36,38-41]. Three studies reported higher baseline
levels of IL-6 [39] and soluble IL-2 receptor [42] and
lower basal levels of IL-10 and IFN-γ [40] in patients with
RA compared with controls.
Baseline leucocyte counts were not significantly differ-
ent between patients with SLE and controls in most
(three of four) studies [43-45]. One study reported base-
line leucopenia in patients with SLE [40]. All studies
reported lower lymphocyte counts (including lower sub-
sets of lymphocytes) in patients with SLE than in controls
[40,43,45]. Despite this baseline lymphopenia, a higher
percentage of B cells (from the total lymphocyte count)
was found once [43]. Only one study reported similar
numbers of helper T and cytotoxic T cells in patients with
SLE and controls [35]. Cytokine (IL-2, IL-4 and IL-6) lev-
els at baseline were not significantly different between
patients with SLE and controls [40]. However, cytokine
levels of IL-10 and IFN-γ at baseline and the sensitivity of
β-adrenoceptors, which are involved in the transduction
of autonomic signals to immune cells, were lower in
patients with SLE than in controls [45]. The one study
with immunological data on patients with JIA reported
higher cytokine levels (IL-6 and IL-8) than in controls at
baseline [46] (see Table 4).
In summary, at baseline autonomic function is similar
in patients with RA and SLE and controls, with only lim-
ited evidence for heightened autonomic function in (a
subgroup of) patients with rheumatic diseases. Neuroen-
docrine function at baseline is also comparable in
patients with RA and SLE and controls, with only three
studies reporting altered cortisol levels in patient groups.
Specific immune variables, mainly (subsets of ) lympho-
cyte counts, appear to be lower in patients with SLE than
in controls.
Psychophysiological responses to stress
An overview of findings is given in Tables 2, 3 and 4.
Self-reported distress
Self-reported distress was increased significantly from
baseline by psychosocial stress in patients with RA [41]
and SLE [45] and in controls. This increase was greater in
patients with RA [41] than in controls. This was not the
case for patients with SLE [45].
ANS variables
The autonomic response to stress was assessed in
patients with RA, SLE, JIA and in a heterogeneous group
of patients with inflammatory arthritis. Results are sum-
marized in Table 2. In patients with RA, experimental
stress increased autonomic activity (heart rate
[29,36,37,41], blood pressure [29,37,41], systemic vascu-
lar resistance [37], pre-ejection period (PEP) [41], plasma
volume [36], skin conductance [29], and plasma (nor)epi-
nephrine levels [40]), with the increase being similar to
that seen in controls in most studies. However, three
studies reported either diminished [29] or more pro-
nounced [37,41] autonomic responses in (a subgroup of )
patients. In patients with SLE, experimental stress
increased autonomic activity (heart rate [45], blood pres-
sure [45], and (nor)epinephrine levels [40,44,45]), the
increase often being similar to that seen in controls
[31,33,40,45]. Only one study observed a diminished
autonomic response (heart rate), but only during one spe-
cific type of stressor (cold) [31]. The one study involving
patients with JIA showed experimental stress to increase
norepinephrine levels to a similar extent in patients and
healthy controls [46]. In one study with a heterogeneous
group of patients with inflammatory arthritis, experi-
mental stress increased autonomic activity (heart rate,
skin conductance, and pupillary constriction) [32], but
this increase was smaller (pupillary constriction) or
greater (galvanic response) than that of controls.
In summary, patients with rheumatic disorders respond
to experimental stress with increased cardiovascular, gal-
vanic and catecholamine responses. Whereas most auto-
nomic responses to stress are similar to those of a control
group, there is partial evidence (five studies) for altered
stress-induced autonomic responses.
Neuroendocrine variables
Neuroendocrine reactivity, mainly measured as changes
in cortisol levels, was assessed in patients with RA and
SLE and in controls (see Table 3). Experimental stress
elicited both an increase [39,41] and (more often) a
decrease [34,35,38,42] in cortisol levels in patients with
RA. ACTH, which is activated upstream of cortisol,
increased in response to stress [34,41]. In addition to the
assessment of HPA axis hormones, one study also
reported an increase in GH levels in response to a stres-
sor [34]. The neuroendocrine response to stress of
patients with RA was not significantly different from that
of controls in most studies, but two studies reported that
cortisol responses were diminished in patients with RA
compared with controls [35,38]. In one study, experimen-
tal stress increased prolactin levels in controls but not in
RA patients [35]. The effect of stress on neuroendocrine
function in patients with SLE was inconsistent, with
stress eliciting a decrease [35] or no change [44] in corti-
sol levels. A lack of responsiveness was also reported in
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Table 5: Autonomic (ANS), neuroendocrine (NE), and immune responses to different stressors in patients with systemic inflammatory rheumatic diseases
Stress paradigm Studies ANS NE system Immune system
Measure Response Measure Response Measure Response
Psychological stress HR ↑ RA[29,37] Cortisol ↓/↑ RA[30] Leucocytes ↑ RA[36]
↑ Arthr[32] 0 SLE[44] ↑ SLE[44]
Cognitive tasks [38]* [29,30,44] SC ↑ RA[29] Lymphocytes ↑ RA[30]
[31]** [42]* ↑ Arthr[32] 0 SLE[44]
[32,36,37] CO ↑ RA[37] T 0 RA[30]
PV ↑ RA[36] 0 SLE[44]
SVR ↑ RA[37] B ↑ RA[30]
BP ↑ RA[29,36,37] 0 SLE[44]
CA ↑ SLE[44] NK ↑ RA[30]
0 SLE[44]
Th 0 SLE[44]
Tcyt ↑ SLE[44]
CRP ↑ RA[36]
Psychosocial [40,41,45] HR ↑ RA[41] Cortisol ↑ RA[41] Leucocytes ↑ RA[40]
tasks ↑ SLE[45] ACTH ↑ RA[41] ↑ SLE[40,45]
BP ↑ RA[41] Lymphocytes ↑ RA[40]
PEP ↓ RA[41] ↑ SLE [40,45]
CA ↑ RA[40] T ↑ RA[40]
↑ SLE[40,45] ↑ SLE[40,45]
Tcyt ↑ RA[40]
↑ SLE[40,45]
NK ↑ RA[40]
↑ SLE [40,45]
Th ↑ RA[40]
0 SLE[40,45]
NK toxicity 0 RA[40]
0 SLE[40,45]
IL-6 ↓ [41]/0 [40] RA
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0 SLE[40]
IL-4 0 RA[40]
↑ SLE[40]
IL-2 0 RA[40]
0 SLE[40]
IL-10 0 RA[40]
0 SLE[40]
IFN-γ 0 RA[40]
0 SLE[40]
TNF-α ↑ RA[41]
β - AR 0 SLE[41]
Exercise [38]* [34,35] Cortisol ↓ RA[34,35] Th ↓ RA[35]
↓ SLE[35] ↓ SLE[35]
ACTH ↑ RA[34] Tcyt 0 RA[35]
GH ↑ RA[34] ↓ SLE[35]
IGF-I 0 RA[34]
PRL 0 RA[35]
0 SLE[35]
Sensory stress
Cold induction [38]* [39] NE ↑ JIA[46] Cortisol ↑ RA[39] Leucocytes ↑ SLE[43]
[31]** [46] Lymphocytes 0 SLE[43]
[33]** T 0 SLE[43]
Heat induction [39] Tcyt ↑ SLE[43]
Acoustic stress [43,42]* B ↑ SLE[43]
Pupillary light [32]** Th ↓ SLE[43]
IL-6 ↑ RA[39]
↑ JIA[46]
TNF-α ↑ RA[39]
↑ = increase in response to stressor, ↓ = decrease in response to stressor, 0 = no response to stressor. RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, JIA = juvenile idiopathic 
arthritis, arthr = heterogeneous group of patients with inflammatory arthritis. * = study not described in Table because more than one stress paradigm was used, ** = study not described in Table 
due to lack of within-subject measurements. HR = heart rate, SC = skin conductance, BP = blood pressure, NE = norepinephrine, CA = catecholamines, PC = pupillary constriction, PV = plasma 
volume, PEP = pre-ejection period, CO = cardiac output, SVR = systemic vascular resistance, C = cortisol, ACTH = adrenocorticotropin hormone, PRL = prolactin, GH = growth hormone, β-AR = β 
adrenoceptor, IGF-I = insulin-like growth factor I, IFN-γ = interferon-γ, TNF-α = tumor necrosis factor α, IL = interleukin, CRP = C-reactive protein, B = B cell, T = T cell, Th = helper T cell, Tcyt = 
cytotoxic T cell, NK = natural killer cell.
Table 5: Autonomic (ANS), neuroendocrine (NE), and immune responses to different stressors in patients with systemic inflammatory rheumatic diseases (Continued)
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control subjects [35,44]. Experimental stress did not
increase prolactin levels in patients with SLE [35].
In summary, although cortisol and ACTH levels change
in response to experimental stress, differences between
patients with rheumatic diseases (RA and SLE) and con-
trol groups have been reported in only two studies. There
is preliminary evidence (one study) that the prolactin
response to stress is different in patients than in controls.
Immune variables
Because several immune variables were used in the vari-
ous studies to assess the effect of experimental stress on
immune function, we have classified results on the basis
of changes in leucocyte and lymphocyte counts and
inflammatory markers (see Table 4).
Leucocytes and (subgroups of) lymphocytes In
patients with RA, experimental stress consistently
increased the number of leucocytes [36,40,42], and
increased the number of lymphocytes [30,40], with
increases in the number of B cells [30], total T cells [40]
and cytotoxic T cells [40] and either an increase [40] or a
decrease [35] in helper T cells. The stress-induced
increase in NK cell numbers [30,40] did not result in an
increase in NK cell activity [40]. Most studies did not
detect a difference in the immune response (leucocyte
and lymphocyte counts) to stress of patients with RA and
controls, but one study reported lower lymphocyte
counts after stress in patients with RA [42]. Changes
compared with controls were noted for helper T cells
[35,40] and cytotoxic T cells [35]. In patients with SLE,
stress induced a consistent increase in the number of leu-
cocytes [40,43-45], and a less consistent increase in the
number of lymphocytes [40,45]. Stress increased the
number of total T cells [40,45], number [40,45] and per-
centage [43,44] of cytotoxic T cells, and the percentage of
B cells [43], and decreased the number of helper T cells
[35,43]. Again, although NK cell numbers increased after
stress [40,45], NK cell activity did not increase [40,45].
Comparison showed that the immune response to stress
was often smaller in patients with SLE than in controls:
the increase in total leucocyte counts in patients with SLE
was smaller than that of controls [40,43,45], as was the
increase in total lymphocyte count [43-45]. Moreover, the
stress-induced change in subsets of lymphocytes was
often smaller for B cells [43,44], total T cell numbers
[44,45], helper T cells [43-45], cytotoxic T cells [35,43],
and NK cells [40,45].
Thus, total leucocyte counts and lymphocyte subsets
change in response to stress in patients with rheumatic
diseases, with patients with SLE having a smaller
response (in addition to their baseline lymphopenia) than
controls; no consistent alterations were found for patients
with RA. NK cell cytotoxicity is diminished in patients
with RA and SLE compared with control.
Inflammatory markers In patients with RA, experimen-
tal stress did not change levels of various inflammatory
markers (IL-2, soluble IL-2 receptor, IL-4, IL-10 and IFN-
γ) [40,42], although levels of CRP [36] and TNF-α
increased after stress [39,41]. Results for IL-6 were incon-
sistent, with stress inducing a decrease [41], an increase
[39] or no change [40] in levels. Patients differed from
controls, having smaller IL-10 and IFN-γ responses [40],
and larger TNF-α [39,41] and CRP responses [36]. In
patients with SLE, experimental stress did not change lev-
els of cytokines and other inflammatory markers (IL-2,
IL-6, IL-10, IFN-γ, β-adrenoceptors) [40,45], although
levels of IL-4 increased after stress [40]. Patients with SLE
differed from controls in their response to stress, having a
larger increase in IL-4, smaller IL-10 and IFN-γ responses
[40], and fewer β-adrenoceptors on monocytes [40,45]. In
patients with JIA, stress did not affect IL-8 production,
but increased IL-6 production [46]. This increase was not
observed in controls. Thus, although in general experi-
mental stress does not seem to influence levels of certain
cytokines and inflammatory markers in patients with
rheumatic diseases (for example, sIL-2, IL-8, IL-10, IFN-
γ, β-adrenoceptors), it does cause specific changes in
CRP and TNF-α in patients with RA, changes in IL-4 in
patients with SLE, and changes in IL-6 in patients with
JIA. These changes are not observed in controls.
In summary, the leucocyte and lymphocyte responses
to stress are smaller in patients with SLE than in controls
but consistent differences with controls are not seen in
patients with RA. Experimental stress does not seem to
affect NK cell cytotoxicity in either patient group. How-
ever, specific stress-induced changes in inflammatory
markers are reported in patients with RA (CRP, TNF-α),
SLE (IL-4) and JIA (IL-6) that are not observed in con-
trols.
Physiological stress reactivity for specific types of stressors
As seen above, experimental stress has a distinct effect on
the autonomic, neuroendocrine, and immune systems.
Below, we summarize the effect of the different types of
experimental stress (cognitive, psychosocial, physical,
and sensory), to determine whether different types of
stress elicit different responses in different patients
groups (see Table 5). Studies in which more than one type
of stressor was used, were not included [38,42] unless
outcome measures were reported separately for the dif-
ferent types of stressors [31,32].
Cognitive stressors
Five studies investigated a cognitive stressor in patients
with RA, SLE, or inflammatory arthritis [29-32,36,37,44].
In all patient groups, cognitive stress consistently
increased autonomic function: heart rate [29,32,37],
blood pressure [29,36,37], skin conductance [29,32], car-
diac output and systemic vascular resistance [37], plasma
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volume [36], and catecholamines [44]. Patients with RA
and SLE had different cortisol responses to cognitive
stress [30,44] (see Table 5). Cognitive stress elicited
changes in leucocyte counts, lymphocyte counts, subsets
of lymphocytes, and CRP levels in patients with RA
[30,36], but only changes in leucocyte counts and cytoxic
T cell numbers in patients with SLE [44].
Psychosocial stressors
A psychosocial stressor was used in three studies of
patients with RA and SLE [40,41,45]. Psychosocial stress
consistently increased autonomic activity (heart rate
[41,45], blood pressure [41], pre-ejection period [41] and
catecholamine levels [40,45]) in patients with RA and SLE
and increased neuroendocrine variables (cortisol and
ACTH [41]) in patients with RA. Some immune
responses were similar in the two patient groups (leuco-
cyte counts, lymphocyte counts, (cytotoxic) T cells, NK
cells and NK cell cytoxicity [40,45]), whereas others were
different (helper T cells [40], IL-4 [40]) (see Table 5).
Cytokine levels were not influenced by psychosocial
stress, with the exception of an increase in IL-4 in
patients with SLE, an increase in TNF-α in patients with
RA, and inconsistent findings for IL-6.
Exercise stressors
The stress of exercise was investigated in two studies with
patients with RA and SLE [34,35]. These studies did not
assess autonomic function; however, cortisol levels
decreased in both groups of patients [34,35] whereas
ACTH levels and GH levels increased [34]. Exercise stress
elicited a different cytotoxic T cell response in patients
with RA and SLE [35] (see Table 5).
Sensory stressors
Sensory stressors were used in six studies involving
patients with SLE and JIA [31-33,39,43,46]. Sensory stress
increased catecholamine levels [46] and cortisol levels
[39]. It also increased leucocyte counts, changed percent-
ages of certain subsets of lymphocytes [43], and increased
levels of IL-6 [39,46] and TNF-α [39] (see Table 5).
In summary, although few data are available about the
effects of specific types of stress, results suggest that psy-
chosocial, cognitive and sensory stress consistently
increase autonomic activity. Changes in neuroendocrine
variables in response to psychosocial, cognitive and sen-
sory stressors are observed in patients with RA only. Psy-
chosocial stress seems to elicit the strongest immune
response in all patient groups studied.
Discussion
A better understanding of the acute physiological
response to stress in patients with inflammatory rheu-
matic diseases might further our knowledge of how stress
affects the health of these patients. We reviewed the
effects of time-limited stressors on autonomic, endo-
crine, and immune variables in patients with chronic
inflammatory rheumatic diseases. Results suggest that
autonomic and neuroendocrine responses to stress are
not consistently altered in patients with rheumatic disor-
ders compared with controls, although patients do appear
to show a distinct immune response to stress. Psychoso-
cial stress might prove to be the best tool to evaluate
these specific immune responses to stress.
Physiological stress response systems
ANS
Although previous studies that used regular autonomic
function tests showed autonomic reactivity to be altered
in different populations of patients with rheumatic dis-
eases compared with controls [2,47-50], we failed to find
consistent evidence for these alterations in studies inves-
tigating psychological, exercise, or sensory stress. The
autonomic function of patients with rheumatic disorders
was not only similar to that of controls at baseline but
also after experimental stress, with cardiovascular, gal-
vanic and catecholaminergic responses largely compara-
ble to those of controls. Only a minority of studies
reported autonomic function to be altered in these
patients (as compared with controls) [29,31,32,37]. Stud-
ies have shown that alterations in autonomic function in
response to stress are correlated with disease severity
[36,37,48,51], which suggests that only subgroups of
patients with severe disease show distinct alterations in
autonomic function. Changes in autonomic function
might also be linked to physical deconditioning, vascular
inflammation and accelerated atherosclerosis [52], which
could explain the inconsistencies in the literature on this
subject. It should also be noted that alterations in auto-
nomic function might reflect a change in sympathetic or
parasympathetic activity or in the balance of the two sys-
tems [53,54]. Autonomic measures used in experimental
stress paradigms (for example, the heart rate response) do
not always differentiate between these systems, in con-
trast to regular autonomic function tests [55], which spe-
cifically aim to distinguish between sympathetic
dysfunction and parasympathetic neuropathy [49,51,56].
HPA axis
The expected increase in neuroendocrine variables in
response to a stressor was only observed in two studies
with patients with RA [39,41]. This increase is consistent
with previous studies reporting significant and consistent
endocrine responses to psychosocial stress both in
healthy subjects and in various patient populations with-
out rheumatic disorders [24,25,41,57-60,60-62]. The
change in cortisol levels is consistent with the endocrine
response to real-life anticipation stress before hip or knee
surgery in patients with RA [63,64]. However, most stud-
ies evaluated in this review reported a decrease in cortisol
levels after stress, both in patients and controls, which
might reflect the normal diurnal rhythmic decline in cor-
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tisol levels instead of a stress response [34,35,38,42]. All
studies, except the two reporting an increase in cortisol
levels, assessed patients in the early morning hours, when
cortisol levels are known to decrease sharply.
Fuelling the ongoing debate on whether or not HPA
axis responses are diminished in patients with rheumatic
disease compared with healthy subjects, we did not find
consistent changes in HPA axis function in response to
psychological and exercise stress in patients with rheu-
matic diseases. Indeed, only two studies showed a differ-
ent neuroendocrine response to stress in patients and
controls [35,38]. Previous studies involving pharmacolog-
ical stimulation of the HPA axis reported either similar or
slightly lower responses in patients with rheumatic dis-
eases compared with controls [27,28]. However, results
should be interpreted with caution because stress manip-
ulation may have been ineffective. Variations across stud-
ies in disease duration and activity, age, sex and sampling
time might contribute to the variability in HPA axis
responses in patients with rheumatic diseases. Moreover,
attention should be paid to the role of pharmacotherapy
(for example, corticosteroids), which could influence the
endocrine response to stress [65].
Immune system
Most studies reported that total leucocyte counts and
specific subsets of lymphocytes (not total number per se)
increased after stress in patients with rheumatic diseases.
The most consistent finding was an increase in the num-
ber of NK cells, as reported in earlier studies showing that
the most robust effect of acute time-limited stressors in
healthy subjects is a marked increase in the number of
NK cells, which suggest an activation of innate immunity
[15]. However, NK cell cytotoxicity after stress was lower
in patients than in controls, possibly due to permanent
activation as a consequence of the inflammatory disease
[40,45]. The change in cytokine levels elicited by stress in
patients with rheumatic disorders was small or inconsis-
tent, for example, for the most frequently measured
cytokine IL-6 [40,41,46]. Previous semi-experimental
studies with patients with RA reported ambiguous
results, reporting either significantly increased [63] or
decreased levels of IL-6 [64] during anticipation of
planned knee or hip arthroplasty. In addition, in a study
evaluating responses to cryotherapy, patients with RA
not treated with glucocorticoids responded with an
increase in IL-6 levels [65]. A recent meta-analysis
showed IL-6 levels to be consistently increased after psy-
chosocial stress in healthy individuals [16]. The contra-
dictory findings regarding cytokine responses in patients
with rheumatic diseases might be due to methodological
caveats, such as failed stress manipulation or small sam-
ple sizes (for example, in Jacobs et al. (2001)). However, it
is also possible that cytokines do not effectively regulate
immune function systemically, but instead near the effec-
tor site [40]. Future studies involving patients with rheu-
matic diseases should measure local immune variables in
samples obtained from joint tissue or synovial fluid
[66,67]. Another explanation is that patients or subgroups
of patients might have different cytokine responses (for
example, TNF-α) because of differences in disease sever-
ity [68] or pharmacotherapy [41,65]. In general, as could
be expected for immune-mediated diseases, the immune
response to stress was different in patients and controls,
and also differed between the various types of inflamma-
tory rheumatic diseases.
Differences in type of stressor, rheumatic disease and (time 
points of) outcome measures
Findings of this review should be interpreted with cau-
tion due to differences in the types of stress induced, the
various rheumatic diseases evaluated, and the variability
in outcome measures and assessment times. In addition,
the highly variable methodological quality of the studies,
the small number of studies, and the relatively small
patient samples hinder an unequivocal interpretation of
findings. Future research urgently requires well-designed
studies with larger numbers of patients. These studies
should, for example, systematically take into account
physiological baseline levels.
Stress paradigms
Only the studies of psychosocial stress evaluated all three
physiological stress response systems (autonomic, neu-
roendocrine and immune) and, moreover, consistently
reported stress-induced increases at all three levels. This
is in line with previous studies showing significant and
consistent autonomic, neuroendocrine, and immune
responses to psychosocial stress in both healthy subjects
and patient groups [25,41,57-60,60-62,69]. In contrast,
cognitive stressors did not consistently alter neuroendo-
crine variables, and immune responses were small in
patients with SLE. The stress of exercise was found not to
activate the HPA axis in patients with rheumatic diseases,
in contrast to what has previously been observed in
healthy subjects [70], although studies suggest that neu-
roendocrine changes are only observed after exercise of
longer duration [71]. Data on immune responses were
very limited. The studies that assessed sensory stress
reported stress-induced increases in autonomic, neu-
roendocrine, and immune function, but data were lim-
ited. Because most sensory stressors are also frequently
applied to induce pain [72,73], future studies of stress
should take into account whether a stressor is pain-
inducing in order to unravel the relationship between
stressors, pain and physiological responses [74]. Overall,
more research into the effects of psychosocial stress on
physiological function is needed, especially because these
stress paradigms seem to generate the strongest response
at all three physiological levels and probably have the
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greatest ecological validity. Importantly, insight in physi-
ological responses to acute stressors cannot automatically
be translated to the field of daily stressors, major stress
events or even chronic stressors [5,75]. For example,
studies in healthy and other disease populations suggest
that chronic stress might induce hypocortisolism [6,76]
and global immunosuppression of both innate and spe-
cific immunity [15]. Overall, there is a lack of studies
examining the association between physiological parame-
ters and chronic stressors in rheumatic populations [2].
Studies investigating stressors in daily life reported an
association between stressors, mainly of an interpersonal
nature, and concentrations of cytokines and lymphocytes
(for example, IL-6, soluble IL-2 receptors and T cell num-
bers) [77-79]. However, results are inconclusive [80] and
future studies are needed to elucidate how acute and
chronic stressors differentially affect inflammatory rheu-
matic diseases.
Disease and treatment characteristics
In contrast to autonomic and neuroendocrine responses,
the immune response elicited seemed to be specific to the
type of inflammatory rheumatic disorder involved, and
this was especially evident for psychosocial stress.
Patients with SLE often have baseline lymphopenia and
this review showed that stress led to diminished cell
mobilization and consequently less pronounced stress-
induced changes in lymphocyte (sub)populations in these
patients compared with controls and patients with RA. In
contrast, patients with RA did not consistently show
these alterations, but only alterations in certain subpopu-
lations of lymphocytes. Furthermore, the cytokine
response to stress might be distinct for different rheu-
matic populations. The effect of pharmacotherapy (for
example, corticosteroids and biologicals) on neuroendo-
crine and immune responses to stress in these popula-
tions is unclear. Only two of 16 studies conducted
subgroup analyses to reveal possible effects of pharmaco-
therapy on response patterns. Motivala et al. (2008)
found significant stress-induced increases in TNF-α only
in patients with RA not treated with TNF-α antagonists
(and no effect of corticosteroid treatment), and Pawlak et
al. (1999) reported no significant difference in physiologi-
cal variables between patients with SLE treated with cor-
ticosteroids and/or disease-modifying antirheumatic
drugs (DMARDs) and non-treated patients [45]. Four
other studies also suggest no effect of pharmacotherapy
(more specifically, DMARDs [38], nonsteroidal anti-
inflammatory drugs (NSAIDs) [34,38], and corticoster-
oids [34,43,44]) on stress reactivity patterns based on
descriptive data. The other studies do not mention possi-
ble effects of pharmacotherapy [29-33,35-37,39,40,42,46].
Clearly, patient samples are often too small to draw
conclusions. More studies comparing different inflamma-
tory diseases and healthy participant are needed to
address the question whether the physiological response
to stress is disease-specific, knowledge which might facil-
itate our understanding of factors contributing to the
maintenance and exacerbation of rheumatic disorders.
Outcome measures
The heterogeneity of outcome measures, especially with
regard to immune variables, makes it difficult to compare
studies of the stress response. Moreover, stressors that
activate the physiological stress system via the hypothala-
mus and subsequent down-stream cascades might induce
alterations in hormones, peptides and cytokines other
than discussed and assessed in this review (for examples,
dehydroepiandosterone (sulfate) (DHEA-S), neuropep-
tide Y (NPY), substance P). Previous studies suggest that
alterations in the stress response in patients with rheu-
matic disorders might be located in the interaction
between the two stress axes (HPA and ANS) and the
immune system, more specifically in the number or sig-
nalling capacity of β-adrenoceptors [45,48,66,81] or glu-
cocorticoid receptors [82-84] on lymphocytes.
Although the HPA axis, ANS, and immune system are
thought to function in an interdependent fashion, only
four of 16 studies in this review investigated outcome
variables that evaluate all three stress response systems.
Cardiovascular reactivity during a mental stress task has
been shown to be associated with the subsequent cortisol
response [25], and cardiovascular responses have been
associated with post stress levels of cytokines such as IL-6
and TNF-α [85]. In addition, HPA axis variables are cor-
related with immune responses after stress [53]. Future
studies should try to integrate the responses of different
systems by simultaneously assessing (para)sympathetic
responses, neuroendocrine variables, and immune fac-
tors, to increase our knowledge of the coordination and
possible dysregulation of these systems [59].
Psychological variables
In addition to assessing the physiological response to
experimental real-life stressors, it is important to con-
sider other key elements of the stress response, such as
the individual's appraisal of the threat of the event, per-
ceived distress, coping behaviour and personality charac-
teristics [4]. As the appraisal of threat might partly
determine the biological stress response of an individual,
self-reported measures of distress appear to be a simple
and adequate manipulation check in studies of psychoso-
cial stress. Furthermore, acute stress responses are
known to be correlated with individual differences in psy-
chological factors, such as coping styles [86], trait anxiety
[87,88], depressed mood [59,89,90], perfectionism [91],
social inhibition [92] and anticipatory cognitive appraisal
[93-96]. However, none of the studies, except one [74],
assessed individual psychological characteristics. In addi-
tion, only two studies in this review assessed stress-
induced self-reported distress [41,42] and only three
de Brouwer et al. Arthritis Research & Therapy 2010, 12:R89
http://arthritis-research.com/content/12/3/R89
Page 21 of 24
studies [36,37,39,41] explicitly excluded affective disor-
ders. Although half of all studies excluded patients with
(severe or chronic) comorbidity, these were mainly physi-
cal in nature. We cannot rule out the possibility that
patients with psychiatric disorders are included in these
studies, obscuring the major research question whether
inflammatory rheumatic diseases are related to a specific
physiological stress responses profile. Future studies of
stress responses in patients with rheumatic diseases
should include individual psychological characteristics
(for example, personality, coping styles) and affective
responses to help identify whether patients differ with
regard to psychophysiological responses to stress.
Time points
Some consideration should be given to when outcomes
are measured. Almost all the studies included at least one
immediate post stress measurement, but only half of the
studies included an additional measurement (mostly 30
or 60 minutes after cessation of the stressor), with only
two studies including more than two follow-up measure-
ments. Cytokine responses may be delayed for minutes or
hours relative to ANS and HPA responses, because cytok-
ines are produced by activated lymphocytes and mac-
rophages [97-99]. This makes it difficult to detect the
peak immune response when collecting only one or two
samples, for example for the increase in IL-6 and IL-1
receptor agonists following psychosocial stress [85].
Additionally, in accordance with the allostatic load con-
cept [100] the ability and time taken by the activated
stress system to return to baseline (recovery period)
might be an important factor in the link between stress
and disease [99,101-103]. Moreover, repeated mental
stress has been linked to a lack of habituation of the corti-
sol response [89,104] and plasma interleukin-6 [99] in
subgroups of individuals. Thus future studies should have
more frequent evaluation time points and investigate
individual differences in the return-to-baseline values
and in habituation patterns after repeated stress.
Conclusions
In summary, this review shows that there is limited evi-
dence that autonomic and neuroendocrine function is
altered after physical or psychological stress in patients
with inflammatory rheumatic diseases compared with
healthy subjects. In contrast, there is evidence that
immune function is altered by stress in a manner specific
to different rheumatic diseases, and thus real-life stres-
sors could contribute to the maintenance or exacerbation
of rheumatic diseases.
Future studies of stress, and particularly psychosocial
stress, should have a follow-up with multiple measure-
ment points, assess different physiological stress systems,
and take into account stress appraisal. As individual dif-
ferences in stress appraisal and stress response patterns
might be important prognostic factors for disease pro-
gression, therapies that focus on stress management may
be important adjuncts to traditional pharmacotherapy in
the treatment of inflammatory rheumatic diseases. Stress
induction studies could prove to be helpful for evaluating
the effectiveness of these interventions [105,106].
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